Study #2023-1048
A phase 2, open-label, multicenter study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in adult participants with relapsed or refractory multiple myeloma (QUINTESSENTIAL)
MD Anderson Study Status
Enrolling
Treatment Agent
Arlocabtagene Autoleucel
Description
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Phase II
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.